Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03443414
Recruitment Status : Completed
First Posted : February 23, 2018
Results First Posted : June 4, 2019
Last Update Posted : June 4, 2019
Sponsor:
Information provided by (Responsible Party):
Verona Pharma plc

Brief Summary:
The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to one of the five treatment options.

Condition or disease Intervention/treatment Phase
COPD Drug: RPL554 suspension Drug: Placebo Phase 2

Detailed Description:

RPL554 is a dual inhibitor of PDE3 and PDE4 which are known to have a role in modulating the inflammatory airway response in respiratory diseases, including COPD. PDE3 inhibitors act as bronchodilators whilst PDE4 inhibitors have anti-inflammatory properties and there is also evidence to suggest that combined inhibition of PDE3 and PDE4 can have additive or synergistic anti-inflammatory and bronchodilator effects. PDE4 inhibitors (administered orally) have, however been associated with unfavorable gastrointestinal side effects such as nausea, emesis, diarrhea, abdominal pain, loss of appetite and weight loss. Dual PDE3/PDE4 inhibitors (administered by inhalation) have exhibited both bronchodilator and anti-inflammatory actions, with a more favorable side effect profile. It is plausible that increased efficacy with reduced side effects may be achievable with administration of a dual PDE3/4 inhibitor by the inhaled route compared to orally administered PDE3 or PDE4 inhibitors.

The purpose of this study is to investigate the dose response of RPL554 in patients with COPD over 4 weeks. This length of time should allow for study of the bronchodilator response, measured predominantly by the peak forced expiratory volume in one second (FEV1), and the anti-inflammatory response, as measured predominantly by trough FEV1.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 405 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Masking Description: The nebuliser cup will be obscured to prevent the Investigator or outcomes assessor so the contents are not visible to the Investigator our outcomes assessor. The visual appearance of the study medication will not be discussed with the subject
Primary Purpose: Treatment
Official Title: Phase IIb, Randomized, Double Blind, Placebo Controlled, Dose Ranging Study to Assess the Effect of RPL554 in Patients With Moderate to Severe COPD.
Actual Study Start Date : June 1, 2017
Actual Primary Completion Date : January 23, 2018
Actual Study Completion Date : February 7, 2018

Arm Intervention/treatment
Experimental: 0.75 mg RPL554 Drug: RPL554 suspension
A dual PDE3/PDE 4 inhibitor

Experimental: 1.5 mg RPL554 Drug: RPL554 suspension
A dual PDE3/PDE 4 inhibitor

Experimental: 3 mg RPL554 Drug: RPL554 suspension
A dual PDE3/PDE 4 inhibitor

Experimental: 6 mg RPL554 Drug: RPL554 suspension
A dual PDE3/PDE 4 inhibitor

Placebo Comparator: Placebo Drug: Placebo
Placebo solution




Primary Outcome Measures :
  1. Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4 [ Time Frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6). ]

    Spirometry assessments were used to assess pulmonary function including the forced expiratory volume in 1 second (FEV1). Peak FEV1 at Week 4 was defined as the maximum post-dose value among the 30 minutes, 1, 2 and 3 hour assessments collected at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. A mixed model for repeated measures (MMRM) was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.

    The least squares (LS) mean change from baseline FEV1 to peak FEV1 (as measured over 3 hours) at Week 4 is presented.



Secondary Outcome Measures :
  1. Mean Change From Baseline FEV1 to Morning Trough FEV1 at Week 4 [ Time Frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6). ]

    Morning trough FEV1 was defined as the last pre-dose value at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.

    The LS mean change from baseline FEV1 to morning trough FEV1 at Week 4 is presented.


  2. Mean Change From Baseline FEV1 to Average FEV1 (Over 12 Hours) at Day 1 and Week 4 [ Time Frame: Baseline (pre-dose, Visit 2), up to 12 hours post-dose at Visit 2 (Day 1) and Visit 6 (Week 4). ]

    Average FEV1 over 12 hours was defined as the area under the curve from 0 to 12 hours post-dose (AUC[0-12]) of the FEV1 values collected during the visit under analysis (Day 1 or Week 4), divided by the length of the time interval of interest (in hours). The AUC was calculated using the trapezoidal rule. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.

    The LS mean change from baseline FEV1 to average FEV1 over 12 hours at Day 1 and at Week 4 is presented.


  3. Mean Change From Baseline in COPD Symptoms Using the Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT-PRO) Scoring at Week 4 [ Time Frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6). ]
    Patients completed an electronic diary (e-diary) once daily which used the 14-item EXACT-PRO instrument to assess COPD symptoms. The EXACT-PRO instrument contains 11 respiratory symptom questions that comprise the derivative Evaluating Respiratory Symptoms (E-RS) instrument that was used to measure the effect of treatment with RPL554 on the severity of COPD symptoms overall. The E-RS tool contains 3 subscales to assess breathlessness, cough/sputum and chest symptoms. In addition to the subscale scores, a total score for the E-RS part was obtained. The raw totals for the E-RS score and for each of the subscales were converted to a scale range of 0 to 100 (least symptomatic to most symptomatic). MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. Baseline was the last non-missing assessment taken prior to investigational product start date.

  4. Mean Change From Baseline in Breathlessness as Assessed Using the St George's Respiratory Questionnaire (SGRQ) at Week 4 [ Time Frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6). ]
    Patients completed the COPD specific SGRQ (SGRQ-C) consisting of 14 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicate a worse outcome. Baseline assessment was pre-dose at Visit 2. MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, patient as random effect. The LS mean change from baseline in the total, symptoms, activity and impact SGRQ-C scores are presented.

  5. Number of Patients With Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to end of study (approximately 6 weeks) ]

    The number of patients with TEAEs for each the following categories are presented: any TEAE, any drug-related TEAE, any severe TEAE, any serious TEAE, serious drug-related TEAE, any TEAE leading to drug interruption, any TEAE leading to drug discontinuation, and any TEAE leading to death.

    All AEs which started after the first dose of investigational product.or started prior to first dose and worsened, based on the Investigator assessment of severity, on or after first dose were considered to be treatment-emergent.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide informed consent
  • Male or female aged 40 to 75 years
  • Meeting specified contraception requirements
  • 12-lead electrocardiogram with heart rate 50-90 beats per minute, QT interval corrected using Fridericia's formula (QTcF) ≤450 msec (males) or ≤470 msec (females), QRS interval ≤120 msec, PR interval ≤200 msec and no clinically significant abnormalities
  • Capable of complying with all study restrictions and procedures, including ability to use the study nebulizer correctly.
  • Body mass index (BMI) 18 to 35 kg/m2 and minimum weight 45 kg.
  • COPD diagnosis with symptoms compatible with COPD for at least 1 year
  • Clinically stable COPD in the previous 4 weeks
  • Ability to perform acceptable and reproducible spirometry.
  • Post-bronchodilator spirometry at screening must demonstrate FEV1/forced vital capacity (FVC) ratio of ≤0.70 and FEV1 must be ≥40 % to ≤80% of predicted normal
  • Chest X-ray (posterior-anterior) at screening, or chest X-ray, magnetic resonance imaging (MRI) or computed tomography (CT) scan in the last 12 months, showing no abnormalities which are both clinically significant and unrelated to COPD.
  • Meet the concomitant medication restrictions and be expected to do so for the rest of the study.
  • Current and former smokers with a smoking history of ≥10 pack years.
  • Capable of withdrawing long acting bronchodilators until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study medication.

Exclusion Criteria:

  • A history of life-threatening COPD including Intensive Care Unit admission and requiring intubation.
  • COPD exacerbation requiring oral steroids in the previous 3 months
  • A history of one or more hospitalizations for COPD in the previous 6 months
  • Lower respiratory tract infection treated with antibiotics in the previous 3 months
  • Evidence of cor pulmonale or clinically significant pulmonary hypertension.
  • Patients with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.
  • Previous lung resection or lung reduction surgery.
  • Oral therapies for COPD (e.g. oral steroids, theophylline, and roflumilast) in the previous 3 months and throughout the study.
  • Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to Visit 1) and remains stable during the trial.
  • A history of, or reason to believe a subject has, drug or alcohol abuse in the previous 3 years.
  • Received an experimental drug within 30 days or five half-lives of the first dose
  • Prior exposure to RPL554.
  • Women who are pregnant or breast-feeding.
  • Patients with a history of current uncontrolled disease that the Investigator believes are clinically significant.
  • myocardial infarction in the previous 6 month; congestive heart failure, a history of unstable or uncontrolled hypertension, or has been diagnosed with hypertension in last 3 months.
  • Use of oral beta blockers.
  • Major surgery (requiring general anesthesia) in the previous 6 weeks, lack of full recovery from surgery at screening, or planned surgery through the end of the study.
  • History of malignancy of any organ system within 5 years, with the exception of localized skin cancers (basal or squamous cell).
  • Clinically significant abnormal values for safety laboratory tests
  • Significant non-compliance in previous investigational studies or with prescribed medications.
  • Requirement for oxygen therapy, even on an occasional basis.
  • Known hypersensitivity to RPL554 or its excipients/components.
  • Abnormal clinically significant 12 lead Holter findings,
  • Any other reason that the Investigator considers makes the subject unsuitable to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03443414


  Show 49 Study Locations
Sponsors and Collaborators
Verona Pharma plc
Investigators
Layout table for investigator information
Principal Investigator: Dr Singh Medicines Evaluation Unit (MEU)
  Study Documents (Full-Text)

Documents provided by Verona Pharma plc:
Statistical Analysis Plan  [PDF] March 6, 2018
Study Protocol  [PDF] April 18, 2017


Layout table for additonal information
Responsible Party: Verona Pharma plc
ClinicalTrials.gov Identifier: NCT03443414     History of Changes
Other Study ID Numbers: RPL554-CO-203
First Posted: February 23, 2018    Key Record Dates
Results First Posted: June 4, 2019
Last Update Posted: June 4, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Verona Pharma plc:
COPD, bronchodilation, FEV1

Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases